A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Purpose
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Condition
- Alzheimer Disease
Eligibility
- Eligible Ages
- Between 65 Years and 80 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning. - Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid and early-tau pathology. - Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities. - Have adequate literacy, vision, and hearing for neuropsychological testing at screening. - Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies - Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy.
Exclusion Criteria
- Mild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition. - Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately ≤5 years. - History of cancer with high risk of recurrence and preventing completion of the trial. - History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis). - Have any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity. - Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker. - Have a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), >4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening. - Have had prior treatment with a passive anti-amyloid immunotherapy <5 half-lives prior to randomization. - Have received active immunization against amyloid beta (Aβ) in any other study. - Have received active immunization against Aβ in any other study. - Current or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD. Addendum 7 Exclusion Criteria for Clinicaltrials.gov: - Same as the main study except contraindications for florbetapir F 18 PET are exclusionary.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Donanemab |
Donanemab administered intravenously (IV) |
|
Placebo Comparator Placebo |
Placebo is administered intravenously |
|
Recruiting Locations
Mesa, Arizona 85206
480-801-9837
Phoenix, Arizona 85006
602-839-6900
Phoenix, Arizona 85013
Tucson, Arizona 85718
520-694-4124
Huntington Beach, California 92648
714-378-2440
Irvine, California 92614
949-753-1663
Long Beach, California 90804
562-606-5999
Napa, California 94558
707-252-9656
Riverside, California 92503
619-915-0496
Sacramento, California 95821
916-434-8230
San Diego, California 92103
619-915-0496
Santa Ana, California 92705
714-542-3008
Santa Rosa, California 95403
707-290-1848
Walnut Creek, California 94598
925-947-2334
Aurora, Colorado 80012
303-337-5707
Basalt, Colorado 81621
970-927-1141
New Haven, Connecticut 06510
203-401-4300
Aventura, Florida 33180
305-933-5993
Bradenton, Florida 34205
941-708-0005
Greenacres City, Florida 33467
561-766-2181
Hialeah, Florida 33012
305-825-6588
Jacksonville, Florida 32216
904-730-0101
Maitland, Florida 32751
Maitland, Florida 32751
407-500-5252
Melbourne, Florida 32940
407-680-0534
Merritt Island, Florida 32952
Miami, Florida 33126
Miami, Florida 33133
786-655-8010
Mount Dora, Florida 32757
352-383-8222
New Port Richey, Florida 34652
727-849-4131
Orlando, Florida 32803
407-337-1000
Orlando, Florida 32819
407-705-3471
Pensacola, Florida 32504
850-438-1136
Port Orange, Florida 32127
386-304-7070
Sun City Center, Florida 33573
855-339-1116
Tampa, Florida 33607
813-800-5252
Tampa, Florida 33613
813-971-8311
The Villages, Florida 32162
352-441-2000
Winter Park, Florida 32789
407-916-0060
Decatur, Georgia 30030
404-537-1281
Gainesville, Georgia 30501
770-534-5154
Woodstock, Georgia 30189
678-494-5735
Boise, Idaho 83704
208-685-0600
Chicago, Illinois 60640
773-275-3500
Indianapolis, Indiana 46227
351-222-6663
Indianapolis, Indiana 46236
269-263-2405
Indianapolis, Indiana 46256
317-537-6099
Waterloo, Iowa 50702
319-272-2112
Louisville, Kentucky 40241
502-394-6460
Lake Charles, Louisiana 70601
337-602-6642
Newton, Massachusetts 02459
617-699-6927
Quincy, Massachusetts 02169
650-796-1586
Waltham, Massachusetts 02451
617-744-1310
Southfield, Michigan 48075
586-276-7453
Bolivar, Missouri 65613
417-328-7781
Las Vegas, Nevada 89128
702-750-000
Springfield, New Jersey 07081
973-850-4622
Charlotte, North Carolina 28210
351-222-5383
Monroe, North Carolina 28112
704-283-7359
Morehead City, North Carolina 28557
252-499-8623
Dayton, Ohio 45459
937-224-8200
Lima, Ohio 45805
351-222-6663
Greenville, South Carolina 29615
864-770-0890
Spartanburg, South Carolina 29303
864-515-0092
Austin, Texas 78757
512-407-8628
Beaumont, Texas 77702
409-331-6040
Georgetown, Texas 78633
351-222-4915
Houston, Texas 77054
713-486-0536
Shavano Park, Texas 78231
210-545-4900
Bennington, Vermont 05201-9810
413-281-0576
Bellevue, Washington 98007
425-453-0404
Tacoma, Washington 98405
253-882-1070
Bayamon, Puerto Rico 00961
(787) 798-4592
More Details
- NCT ID
- NCT05026866
- Status
- Recruiting
- Sponsor
- Eli Lilly and Company
Study Contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or1-317-615-4559
clinical_inquiry_hub@lilly.com